Evidence map›Paper›PMID 40204724›Full record

ArticleCell death & disease2025

MTCH2 regulates NRF2-mediated RRM1 expression to promote melanoma proliferation and dacarbazine insensitivity.

Xuedan Zhang, Enjiang Li, Yingmin Kuang, Yanlong Gai, Yu Feng, Yu Huang, Zhenyan Wei, Junzi Niu, Song Yu, Zhe Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xuedan Zhang *Department of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.
Enjiang Li *Department of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.
Yingmin Kuang *Department of Organ Transplantation, First Affiliated Hospital of Kunming Medical University, Kunming, 650500, Yunnan, China.ORCID http://orcid.org/0000-0001-9834-5776
Yanlong GaiDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.
Yu FengDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.ORCID http://orcid.org/0009-0004-2316-8882
Yu HuangDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.
Zhenyan WeiDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.
Junzi NiuDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.
Song YuDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.
Zhe YangDepartment of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming, 650500, Yunnan, China.
Qiao ZhangDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China.
Buqing SaiDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China. saibuqing@kmmu.edu.cn.ORCID http://orcid.org/0000-0002-0681-4203
Yuechun ZhuDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, 650500, Yunnan, China. zhuyuechun@kmmu.edu.cn.ORCID http://orcid.org/0000-0002-7236-8942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is among the 10 most prevalent malignant tumors, posing a significant threat to human health. A detailed understanding of the molecular mechanisms driving its progression is crucial for advancing treatment strategies and outcomes. Based on bioinformatic analysis and experimental validation, this study identified mitochondrial carrier homolog 2 (MTCH2) as a key regulator of melanoma proliferation. Mechanistically, MTCH2 enhanced the expression and nuclear translocation of nuclear factor (erythroid-derived-2)-like 2 (NRF2), which up-regulated ribonucleotide reductase subunit M1 (RRM1) expression, thereby promoting melanoma cell proliferation. Targeting RRM1 in combination with dacarbazine significantly inhibited tumor growth in nude mouse xenograft models. These findings elucidate a mechanistic link between MTCH2 and the NRF2-RRM1 axis in melanoma proliferation and highlight potential therapeutic targets for intervention.

Indexed as

DacarbazineDrug Resistance, NeoplasmMelanomaNF-E2-Related Factor 2Tumor Suppressor ProteinsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudeRibonucleoside Diphosphate ReductaseXenograft Model Antitumor AssaysDacarbazineNFE2L2 protein, humanNF-E2-Related Factor 2Ribonucleoside Diphosphate ReductaseRRM1 protein, humanTumor Suppressor Proteins

Identifiers

PMID40204724
PMCPMC11982210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.